Bi-Weekly UpdateSep 28, 2026 · 7 pages · Free to read

Pharmaceuticals Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

A bi-weekly roundup of pharmaceutical sector share-price moves, company news and M&A activity for September 14–28, 2026, built for operators, acquirers and advisers tracking commercial-stage and development-stage names across the space.

Download PDF Download PowerPoint

-0.7%
Covered-set median move: +0.8%
S&P 500 return: +7.5%
Supernus Pharmaceuticals (SUPN) move: 10.9x
Trailing EV/EBITDA multiple

1 of 7

$C:\Users\dawoo\OneDrive\Desktop\Deployments\neuracap_sector_reports_fable\Code\NeuraCap_Sector_Report_Pipeline_v2.1.0\ncsr\deck_kit\assets\logo_light_full.png$

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS

Buyers Reward Commercial Certainty While Developers Carry the Overhang

This update covers the sector's movers, company news and transactions for September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI   ·   Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Pharmaceuticals Bi-Weekly Update   |   September 14–28, 2026   |   Confidential   |   Not investment advice

Sources & methodology

1

1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS

Executive summary

Across the 19 names we cover, the set split down the middle: the median move was -0.7% against +0.8% for the S&P 500 over September 14–28, 2026. Development-stage names carrying investor-litigation notices led the fallers, while a proposed sale drove Supernus Pharmaceuticals (SUPN) to the period's strongest gain of +7.5%. One new transaction joined the M&A record without disclosed consideration, leaving the trailing 10.9x EV/EBITDA multiple as the reference. Business model, not sector membership, set the direction.

Key findings

Covered set split evenly; median move of -0.7% trailed the S&P 500's +0.8%.
Investor-litigation notices clustered on development-stage names, pressuring shares.
A proposed sale drove the period's largest gain, Supernus Pharmaceuticals (SUPN) +7.5%.
One new bid joined the M&A record; trailing multiple held at 10.9x EV/EBITDA.

What each page shows

The analyst’s walkthrough of the deck, page by page.

01
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS
Cover slide introducing the September 14–28, 2026 pharmaceuticals bi-weekly update.
We open this bi-weekly pharmaceuticals update by framing what moved, why, and what transacted across September 14–28, 2026. The pages that follow translate that record into decisions for operators, buyers and advisers.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS Buyers Reward Commercial Certainty While Developers Carry the Overhang This update covers the sector's movers, company news and transactions for September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
02
THE BI-WEEKLY BOTTOM LINE
Business Model Set the Direction; Deal Talk and Legal Notices Did the Rest
Summarizes the two-week period's market moves, key events and one transaction across 19 covered names.
Across the 19 names we track, the covered set split down the middle, with a median move of -0.7% versus +0.8% for the S&P 500. Investor-litigation notices clustered on development-stage names, while a proposed sale drove the period's strongest gain in Supernus Pharmaceuticals (SUPN) at +7.5%. One new transaction joined the M&A record, leaving the trailing multiple unchanged. So what: business model, not sector membership, explains who moved and why.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Business Model Set the Direction; Deal Talk and Legal Notices Did the Rest The two-week period in one page · 19 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 The Covered Set Split Down the Middle, with the Median Just Below Flat 10 of 19 covered names fell; the median move was -0.7%, while the S&P 500 returned +0.8% over the same two-week period. 2 Investor-Litigation Notices Clustered on the Development-Stage Cohort Phathom Pharmaceuticals, Inc. (PHAT) fell -15.3% and LENZ Therapeutics, Inc. (LENZ) fell -11.4%, each with an investor-investigation notice published in the window. Disc Medicine, Inc. (IRON) drew one as well. 3 A Proposed Sale Put the Period's Largest Gain on the Board Supernus Pharmaceuticals, Inc. (SUPN) rose +7.5%, the strongest move in the covered set, in a window when a law firm said it was reviewing the price and process of the proposed sale. 4 One Transaction Joined the Record and the Reference Multiple Held Huadeng Tech BioArray Ventures Ltd's announced bid for 111 Inc. was the period's single new transaction, with no disclosed consideration. The trailing median across 30 precedent transactions stands at 10.9x EV/EBITDA. +7.5% Best mover — SUPN worst: BIOA -15.3% · 9 up / 10 down of 19 covered -0.7% Sector median two-week return vs S&P 500 +0.8% 1 Transactions announced in the two-week period terms not fully disclosed
03
PUBLIC MARKET MOVERS
Deal Talk Lifted One Name; Litigation Notices Shadowed the Fallers
Shows the biggest share-price movers in the covered set and links each move to the recorded filing or headline behind it.
Phathom Pharmaceuticals (PHAT) fell -15.3% and LENZ Therapeutics (LENZ) fell -11.4%, each following an investor-investigation notice published in the window; Disc Medicine (IRON) drew a similar notice. Supernus Pharmaceuticals (SUPN) rose +7.5%, the period's largest gain, coinciding with a law firm's review of its proposed sale price and process. The sector median move of -0.7% trailed the S&P 500's +0.8% return over the same two weeks. So what: legal notices and deal talk, not sector-wide sentiment, separated the winners from the fallers.
Everything on this page
PUBLIC MARKET MOVERS Deal Talk Lifted One Name; Litigation Notices Shadowed the Fallers Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -0.7% · S&P 500 +0.8% · materiality bar ±7.4% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -0.7% BioAge Labs Inc. (BIOA) -15.3% No notable in-window news was identified that clearly explains the move. BioAge Labs Inc. (BIOA) fell -15.3% against a median of -0.7% across the covered set. Small developers can travel far from the covered-set median inside a single window. UNEXPLAINED Phathom Pharmaceuticals, Inc. (PHAT) -15.3% Phathom Pharmaceuticals, Inc. (PHAT) fell -15.3%, with a -9.9% day on Sep 23. Shares moved following a Sep 16 announcement of a shareholder fraud investigation; a Sep 17 report noted a new 12-month low, trading as low as $7.66. Discount-tier developers carry legal overhang straight into the share price. COMPANY-SPECIFIC Alkermes plc (ALKS) -12.4% No notable in-window news was identified that clearly explains the move. Alkermes plc (ALKS) fell -12.4% against a median of -0.7% across the covered set. Even a Premium-tier name can finish a two-sided window well below the covered-set median. UNEXPLAINED Supernus Pharmaceuticals, Inc. (SUPN) +7.5% Supernus Pharmaceuticals, Inc. (SUPN) rose +7.5%. The move appears to reflect its proposed sale being in public view: on Sep 24 a law firm said it is investigating the adequacy of the price and process of that sale. A proposed sale still sets the price conversation for commercial specialty portfolios. COMPANY-SPECIFIC
04
MAJOR NEWS & INDUSTRY CATALYSTS
Commercial Franchises Shipped Operating News While Developers Drew Legal Notices
Lists the two-week period's highest-impact company news items, each linked to its source filing or article.
Elanco Animal Health (ELAN) confirmed its U.S. Pet Health business is tracking to plan for the second half, Organon & Co. (OGN) had an FDA filing accepted for review, and Merck & Co. (MRK) added a clinical collaboration. Development-stage names, by contrast, drew investor-litigation notices rather than operating catalysts. So what: commercial franchises kept shipping operating news while developers carried a legal overhang.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS Commercial Franchises Shipped Operating News While Developers Drew Legal Notices The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · NEWS · PRNewsWire Elanco says its U.S. Pet Health business is tracking to its second-half growth plan Elanco Animal Health Incorporated (ELAN) tied the confirmation to demand in tick and itch season and share gains in its base business. Payer-insulated animal health revenue keeps earning the top of the pricing range. Sep 14 · NEWS · GlobeNewsWire Johnson & Johnson partner reports full Phase 1 cohort results for JNJ-1900 in recurrent lung cancer All 24 patients completed treatment with no dose-limiting toxicities and a one-year locoregional control rate of 79%. Majors are still building replacement revenue asset by asset, not in one step. Sep 14 · NEWS · GlobeNewsWire Merck signs a clinical collaboration and supply agreement to pair Keytruda with a radiopharmaceutical Merck & Co., Inc. (MRK) bought a look at a new mechanism through a supply and collaboration structure rather than an acquisition. That is the cheapest way for a Core-tier major to hold a position while a trial runs. Much of the value transfer here moves through deal terms rather than acquisitions. Sep 14 · NEWS · GlobeNewsWire A Sanofi rare-disease executive joins the board of a rare-disease developer ahead of commercialisation The appointment brings rare-disease commercialisation and partnering experience to a company approaching launch. Who a developer recruits is a readable signal about where it thinks its launch execution risk sits. Launch execution credentials are being treated as an asset in rare disease. Sep 14 · NEWS · Business Wire Organon's filing to extend the approved duration of its hormone-free IUD is accepted for FDA review Organon & Co. (OGN), a Discount-tier name, is working the label on an in-market product rather than waiting on the pipeline. Label work on marketed products is a low-cost way to lengthen a commercial runway. Sep 14 · NEWS · GlobeNewsWire Sanofi agrees a strategic partnership covering its mature medicines portfolio Sanofi (SNY) is separating an established-brand portfolio from its growth assets and putting it with a partner built to run it for cash conversion. Established-brand portfolios keep finding owners built to run them for cash.
05
M&A & STRATEGIC ACTIVITY
One New Bid Joins the Record While the Trailing Multiple Sets the Reference
Presents the period's one announced transaction alongside the trailing precedent-transaction multiple.
Huadeng Tech BioArray Ventures Ltd's bid for 111 Inc was the period's single new transaction, announced without disclosed consideration. The trailing median across precedent transactions stands at 10.9x EV/EBITDA and remains the working reference for commercial assets. So what: with only one record added, acquirers still have to underwrite deals against last period's multiple, not a fresh one.
Everything on this page
M&A & STRATEGIC ACTIVITY One New Bid Joins the Record While the Trailing Multiple Sets the Reference 1 transaction announced · September 14–28, 2026 · figures link to the filing Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 Sep 17 n/a Huadeng Tech BioArray Ventures Ltd Huadeng Tech BioArray Ventures Ltd announces a bid for 111 Inc. EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The record carries the transaction as announced on Sep 17 with no disclosed consideration HOW THE TARGET WAS VALUED No enterprise value, EV/revenue or EV/EBITDA was disclosed for this transaction. The reference point stays the trailing median of 10.9x EV/EBITDA across 30 precedent transactions.
06
WHAT IT MEANS
What This Two-Week Period Changes for Operators, Buyers and Advisers
Translates the two-week period's evidence into implications for operators, acquirers and advisers.
Names presenting confirmed operating trajectories on marketed products held their ground better than those without such evidence. Acquirers gained one new transaction record but no new multiple, so the trailing 10.9x EV/EBITDA reference across precedent deals still holds. Advisers can lead with business model — diversified majors, development-stage therapeutics and specialty manufacturers — before layering in the period's evidence. So what: business model, not sector membership, set direction across these two weeks.
Everything on this page
WHAT IT MEANS What This Two-Week Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 P / E (CY2027E) median 11.6x 21 companies in the study 3 valuation tiers Standing thesis: Pharmaceuticals split into diversified majors, development-stage therapeutics and specialty manufacturers FOR OWNERS & OPERATORS Evidence of In-Market Demand Travelled Best Companies in the space traded in both directions, and the names presenting confirmed operating trajectories on marketed products held their ground. FOR ACQUIRERS The Reference Set Gained One Record and No New Multiple One transaction was added during the period and consideration was not disclosed, so the trailing median of 10.9x EV/EBITDA across 30 precedent transactions remains the working reference for commercial assets. FOR ADVISORS Lead with Business Model, Then with the Evidence The standing view splits the sector into diversified majors, development-stage therapeutics and specialty manufacturers
07
SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
Explains the data sources and methodology behind every figure and claim in this update.
Every figure in this update links back to the record it was taken from — filings and market prices through 2026-09-28. This page sets out how we built the update so each claim can be traced to its source.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Pharmaceuticals Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T172636Z_550_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: prnewswire.com · globenewswire.com · businesswire.com · sec.gov

Sources and methodology

This update covers Pharmaceuticals over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 19 listed companies whose core business is Pharmaceuticals under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: AbbVie Inc. (ABBV), Alkermes plc (ALKS), ANI Pharmaceuticals, Inc. (ANIP), BioAge Labs Inc. (BIOA), Design Therapeutics, Inc. (DSGN), Elanco Animal Health Incorporated (ELAN), Fennec Pharmaceuticals Inc. (FENC), Grifols, S.A. (GRFS), Disc Medicine, Inc. (IRON), Johnson & Johnson (JNJ), LENZ Therapeutics, Inc. (LENZ), Merck & Co., Inc. (MRK), Novartis AG (NVS), Organon & Co. (OGN), Phibro Animal Health Corporation (PAHC), Pfizer Inc. (PFE), Phathom Pharmaceuticals, Inc. (PHAT), Sanofi (SNY), Supernus Pharmaceuticals, Inc. (SUPN). 2 names below the floor were excluded from the statistics: FBIO, PLRX.

Window and company universe

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 1 was announced inside the window. The trailing record of 30 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

More coverage in Health Care

Want this analysis for a company in Pharmaceuticals?

Company valuation reports run the same method against a single business — public or private.

Get your report Talk to advisory

Pharmaceuticals Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Key figures

Read the report

Executive summary

Key findings

What each page shows

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › PHARMACEUTICALS

Business Model Set the Direction; Deal Talk and Legal Notices Did the Rest

Deal Talk Lifted One Name; Litigation Notices Shadowed the Fallers

Commercial Franchises Shipped Operating News While Developers Drew Legal Notices

One New Bid Joins the Record While the Trailing Multiple Sets the Reference

What This Two-Week Period Changes for Operators, Buyers and Advisers

Sources, Methodology and Important Notice